- Home
- Latest
- By speciality
- Biology
- Bone
- Brain and nervous system
- Breast
- Colorectal and gastrointestinal
- Community
- Diagnostics
- Drug development
- Epidemiology and prevention
- Haematology oncology
- Head and neck
- Hepatobiliary pancreatic
- Lung and pleura
- Melanoma and skin
- Ovary and gynaecology
- Paediatric
- Prostate and urology
- Psycho social
- Radiotherapy
- Sarcomas
- Surgery
- Other
- By congress
- By continent
- Latest technologies
- Most viewed
- Archive
- Contact us
- FAQ's
- Register
ASCO 2009, Breast, Drugs in development, Europe
Flash player required
You do not have the correct version of the flash player required to view this content. Click here to install the free Adobe flash player.
Dr Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London, UK
Olaparib induces tumour response as single agent in BRCA-deficient breast cancer
Andrew Tutt, MB, ChB, PhD, Kings College London, United Kingdom, speaking at ASCO 2009: PARP Inhibitor Olaparib Induces Tumor Response as Single Agent in BRCA-Deficient Breast Cancer: A small, Phase II international multi-center study reports that more than a third of women with BRCA1 or BRCA2 mutations and advanced breast cancer that persisted despite prior treatment experienced tumour shrinkage after receiving the investigational PARP inhibitor olaparib.
Specialities
- Biology (58)
- Bone (16)
- Brain and nervous system (14)
- Breast (143)
- Colorectal and gastrointestinal (32)
- Community (61)
- Diagnostics (27)
- Drug development (49)
- Epidemiology and prevention (42)
- Haematology oncology (39)
- Head and neck (17)
- Hepatobiliary pancreatic (15)
- Lung and pleura (30)
- Melanoma and skin (22)
- Ovary and gynaecology (29)
- Paediatric (17)
- Prostate and urology (32)
- Psycho social (19)
- Radiotherapy (18)
- Sarcomas (13)
- Surgery (24)
Content is the view and comment of the speakers or author and not of sponsoring companies or organisations. Organisation logo does not indicate endorsement.
Comments on this video Report unsuitable comment
No comments have been made on this video yet, be the first to voice your opinion, use the form on the right.
Add a comment